News

  • 21 September 2015

    Sonendo®, Inc., the developer of a transformative technology for the endodontic marketplace, today announced that the Company has appointed Christopher Rabbitt as Chief Commercial Officer.

  • 9 September 2015

    Genkyotex, the leading developer of selective NOX inhibitors, announced today top-line data from its Phase 2 clinical program with GKT137831, its lead NOX1&4 inhibitor. In patients with diabetic kidney disease, GKT137831 demonstrated an excellent safety profile and statistically significant reduction in both liver enzyme and inflammatory marker levels. Treatment with GKT137831 for 12 weeks resulted in fewer adverse events than placebo, confirming its excellent safety profile. However, a reduction in albuminuria, the primary efficacy endpoint of the study, was not achieved within this timeframe

  • 31 August 2015

    Sonendo®, Inc., the developer of a transformative technology for the endodontic marketplace, today announced that the Company has appointed Bob Anthony as Vice President of Operations. Mr. Anthony will be responsible for Sonendo’s supply chain, including purchasing, manufacturing, manufacturing engineering, field support and facilities.

  • 19 August 2015

    Arsanis, Inc., a developmentstage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, today announced the appointment of Rene Russo, PharmD, BCPS as Chief Development Officer. Dr. Russo, most recently Vice President, Global Medical Affairs at Cubist Pharmaceuticals (acquired by Merck in 2015), will be a member of the Arsanis executive team and will provide strategic planning and leadership for the clinical development of ASN100, Arsanis’ lead program for the prevention and treatment of severe Staphylococcus aureus infections, and other pipeline product candidates.

  • 10 August 2015

    Being a player in a space as competitive as transcatheter aortic valve replacement (TAVR) takes some serious financial backing. Jenavalve Technology (Irvine, Calif.) has risen to that challenge multiple times, most recently with a $26.5 million Series C expansion round to support its growth in the global TAVR market.